This Phase I expansion study reported on the safety and efficacy of the pan-AKT inhibitor, capivasertib, in combination with the ER antagonist, fulvestrant, in a genomically selected advanced ER+ BC population harboring an eligible deleterious PTEN gene alteration in the tumor. This evidence concerns the gene ESR1 and neoplasm.